Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer

Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer

Abstract Background Controversy exists regarding the optimal sequence of chemotherapy among women with operable node‐negative breast cancers with high‐risk tumor biology. We evaluated national patterns of neoadjuvant chemotherapy (NACT) use among women with early‐stage HER2+, triple‐negative (TNBC),...

Full description

Bibliographic Details
Main Authors: Ipshita Prakash, N. Ben Neely, Samantha M. Thomas, Sarah Sammons, Rachel C. Blitzblau, Gayle A. DiLalla, Terry Hyslop, Carolyn S. Menendez, Jennifer K. Plichta, Laura H. Rosenberger, Oluwadamilola M. Fayanju, E. Shelley Hwang, Rachel A. Greenup
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Cancer Medicine
Subjects:
breast cancer
cancer management
clinical management
neoadjuvant chemotherapy
surgical oncology
Online Access:https://doi.org/10.1002/cam4.4517

Internet

https://doi.org/10.1002/cam4.4517

Similar Items